In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

This week’s IND update looks at FT536, a gene-edited natural killer cell therapy developed by Fate Therapeutics for the treatment of multiple solid...

Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics

Multiple new deals and developments and new base editor data from Intellia Therapeutics